Expanded manufacturing enhances life science capabilities

ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its position as a key partner in biopharmaceutical development and production. The expansion includes the commissioning of a 1000L-scale GMP production line for protein manufacturing and the completion of construction on a dedicated virus manufacturing facility. These investments enhance ProBioGen’s ability to support partners from early-stage development through to commercial production, addressing the increasing demand for biologics and viral vector-based therapies.

In protein manufacturing, ProBioGen uses its CHO.RiGHT® platform alongside market-proven technologies such as the DirectedLuck® transposase and the ADCC enhancement GlymaxX®. These innovations strengthen the company’s capacity to deliver high-quality biologics manufacturing solutions, ensuring scalability, efficiency, and regulatory compliance. With the addition of new manufacturing infrastructure, ProBioGen is well-positioned to meet the evolving needs of the biopharmaceutical industry while maintaining its reputation for cutting-edge process development and optimisation.

In viral vector production, ProBioGen continues to build on its extensive expertise in developing proprietary manufacturing platforms. The company offers customised cell lines for viral vector and virus-like particle (VLP) production, including stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) manufacturing. These capabilities address the unique challenges of gene therapy and vaccine production, enabling the development of next-generation therapies with greater precision and efficiency.

“These strategic expansions mark a major milestone for ProBioGen as we continue to scale up and support the growing needs of our customers,” said Dr Alfred Merz, Chief Executive Officer at ProBioGen. By increasing capacity, enhancing viral vector manufacturing, and advancing proprietary technologies, ProBioGen remains committed to providing tailored solutions that drive innovation in biopharmaceutical manufacturing.

With a strong track record in cell line development, process optimisation, and GMP manufacturing, ProBioGen continues to be a trusted partner for life science innovators worldwide. The latest expansion reflects the company’s ongoing dedication to quality, innovation, and the advancement of biopharmaceutical manufacturing.

More information online